LoginSignup
image de profil
Chris Lee
@Vestin
9Mo·

News: $IBRX (+2,01 %) US FDA approves bladder cancer therapy from ImmunityBio!


Very positive for the rest of the pipeline ... lets go!



5
9 Commentaires
image de profil
PaulPaulsonle@PaulPaulsonle
9Mo
I opened a mini position, I'm very excited
•
2
•
Fuchs89@nit
9Mo
a milestone in cancer therapy. I have been invested since 2021 and will hold for a long time
•
1
•
image de profil
Chris Lee@Vestin
9Mo
@nit I am also invested and very confident. Great company and only at the beginning.
•
1
•
image de profil
TrendingRobin@TrendingRobin
8Mo
Also invested since 2021 and looking forward to the development
•
1
•
image de profil
Hugo_Offiziell@_Hugo_
8Mo
You did everything right 👍🏻. Once again, I hesitated too long 🙄
••
image de profil
PaulPaulsonle@PaulPaulsonle
8Mo
Do any of you know why they have already risen 9% in pre-market trading today?
Greetings
••
Fuchs89@nit
8Mo
@PaulPaulsonle
https://finance.yahoo.com/news/immunitybio-executive-chairman-dr-patrick-120000920.html

Patrick Soon-Shiong will present the implications and results of N-803 (ANKTIVA) at the annual meeting of the AUA (American Urological Association).
••
image de profil
PaulPaulsonle@PaulPaulsonle
8Mo
Thank you very much👌👌👌👌
I'm currently considering whether I should increase my position by a lot before the stock market opens in America😅
Do you think that's a good idea?
••
Fuchs89@nit
8Mo
@PaulPaulsonle I can't tell you, as I don't have a crystal ball ^^ With a market cap of over 5 billion, a lot of future performance is of course already priced in. Personally, I think that risk/reward is very attractive in both the short and long term. However, you should not rely on other opinions, but do your own research and adjust your position according to your risk management.
(not investment advice)
••
Participez à la conversation
S'inscrireConnexion